Advertisement

Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma

November 16th 2022, 2:00pm

SITC Meeting

The combination of sotigalimab and pembrolizumab showed encouraging antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

Dr. Halmos on Trastuzumab Deruxtecan in NSCLC

November 14th 2022, 9:20pm

PER® New York Lung Cancer Symposium

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations

November 14th 2022, 9:10pm

PER® New York Lung Cancer Symposium

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC

November 14th 2022, 8:55pm

PER® New York Lung Cancer Symposium

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

Osimertinib Remains the Preferred Frontline Choice for EGFR-Mutated NSCLC

November 14th 2022, 7:55pm

PER® New York Lung Cancer Symposium

Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.

Targeting the ‘New Kids on the Block’ in NSCLC: EGFR Exon 20 and MET Exon 14 Skipping Mutations

November 14th 2022, 7:24pm

PER® New York Lung Cancer Symposium

Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13th 2022, 11:00am

SITC Meeting

CYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung cancer, triple-negative breast cancer, and bladder cancer cell lines, according to preclinical data.

Clinical Trials Propel New Standards of Care for Thyroid Cancer

November 12th 2022, 11:00am

PER® Chemotherapy Foundation Symposium (CFS)

Alan L. Ho, MD, PhD, discusses targeted therapies such as TKIs that have demonstrated promising efficacy in multiple patient populations as well as the agents lenvatinib and pembrolizumab.

Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing

November 12th 2022, 4:10am

LUGPA Annual Meeting

All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.

Sequencing Considerations in mCRPC Treatment Grow Increasingly Complex

November 11th 2022, 11:06pm

LUGPA Annual Meeting

For patients with metastatic castration-resistant prostate cancer who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, as these factors affect downstream options and sequencing.

Dr. Levy on the Future of Atezolizumab in NSCLC

November 11th 2022, 9:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Benjamin Philip Levy, MD, discusses potential future uses for atezolizumab in non–small cell lung cancer.

Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer

November 11th 2022, 9:01pm

LUGPA Annual Meeting

As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.

ADT Alone, With Docetaxel Is Not Enough: ADT Intensification Is SOC for Metastatic Castration-sensitive Prostate Cancer

November 11th 2022, 7:25pm

LUGPA Annual Meeting

Because androgen deprivation therapy alone or with docetaxel is not recommended for most patients with metastatic castration-sensitive prostate cancer, a decision must be made between leveraging couplets vs triplets.

Dr. Albala on the Advantages of PSMA-PET Imaging in Prostate Cancer

November 11th 2022, 5:00pm

LUGPA Annual Meeting

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPC

November 11th 2022, 5:00pm

LUGPA Annual Meeting

Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.

Dr. Shore on the Importance of Genetic Testing in Prostate Cancer

November 11th 2022, 5:00pm

LUGPA Annual Meeting

Neal Shore, MD, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer.

Role of PSMA-PET Expands in the Treatment of Prostate Cancer

November 11th 2022, 4:46pm

LUGPA Annual Meeting

David Albala, MD, discusses integrating PSMA-PET imaging into the clinic and determining which patients with prostate cancer are prime candidates.

Pembrolizumab/Eftilagimod alpha Combo Shows Durable Responses in Frontline NSCLC

November 11th 2022, 3:45pm

SITC Meeting

The first-line combination of pembrolizumab and eftilagimod alpha elicited a 40.4% (95% CI, 31.3%-50.0%) overall response rate by immune RECIST criteria in the intent-to-treat population in patients with advanced non–small cell lung cancer, according to updated findings from the phase 2 TACTI-002 trial.

Dr. Siefker-Radtke on Erdafitinib in Urothelial Carcinoma

November 11th 2022, 2:45pm

LUGPA Annual Meeting

Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.

Dr. Carvajal on Unique Prognostic Factors in Uveal Melanoma

November 11th 2022, 2:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Richard D. Carvajal, MD, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma.

Advertisement
Advertisement